Rallybio Corporation
$8.29
▲
0.36%
2026-04-21 09:10:01
www.rallybio.com
NCM: RLYB
Explore Rallybio Corporation stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$43.48 M
Current Price
$8.29
52W High / Low
$11.49 / $1.9
Stock P/E
—
Book Value
$10.97
Dividend Yield
—
ROCE
-56.97%
ROE
-15.01%
Face Value
—
EPS
$-1.59
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
14
Beta
-1.2
Debt / Equity
0.3
Current Ratio
14.51
Quick Ratio
14.5
Forward P/E
-1.56
Price / Sales
52.03
Enterprise Value
$-9.92 M
EV / EBITDA
0.32
EV / Revenue
-11.56
Rating
None
Target Price
—
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Enveric Biosciences, Inc. | $3.65 | — | $3.44 M | — | -210.04% | -3.04% | $17.84 / $1.71 | $3.94 |
| 2. | Edesa Biotech, Inc. | $6.75 | — | $49.5 M | — | -57.24% | -96.39% | $9.37 / $0.72 | $0.56 |
| 3. | Kalaris Therapeutics, Inc. | $6.6 | — | $132.49 M | — | -41.2% | -3.08% | $11.88 / $2.14 | $3.44 |
| 4. | Senti Biosciences, Inc. | $1.14 | — | $34.26 M | — | -171.08% | -2.18% | $5.1 / $0.77 | $0.18 |
| 5. | Jupiter Neurosciences, Inc. | $0.46 | — | $15.86 M | — | -73.72% | -7.39% | $3.33 / $0.31 | $0 |
| 6. | Aldeyra Therapeutics, Inc. | $1.78 | — | $105.92 M | — | -79.69% | -58.73% | $6.17 / $1.07 | $0.74 |
| 7. | CalciMedica, Inc. | $0.66 | — | $9.49 M | — | -235.71% | -7.61% | $7.2 / $0.46 | $-0.43 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0.22 M | 0.21 M | 0.21 M | 0.21 M | 0.04 M | — |
| Operating Profit | -6.41 M | -6.92 M | -10.06 M | -9.67 M | -11.61 M | — |
| Net Profit | -5.85 M | 16.02 M | -9.7 M | -9.44 M | -11.04 M | — |
| EPS in Rs | -1.11 | 3.03 | -1.83 | -1.78 | -2.09 | -2.08 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0.86 M | 0.64 M | 0 M | 0 M |
| Operating Profit | -33.06 M | -60.5 M | -78.93 M | -67.88 M |
| Net Profit | -8.98 M | -57.77 M | -74.56 M | -66.65 M |
| EPS in Rs | -1.7 | -10.92 | -14.1 | -12.6 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 62.26 M | 68.11 M | 115.62 M | 180.44 M |
| Total Liabilities | 4.3 M | 6.45 M | 9.44 M | 11.12 M |
| Equity | 57.96 M | 61.65 M | 106.18 M | 169.32 M |
| Current Assets | 61.25 M | 67.84 M | 114.79 M | 179.5 M |
| Current Liabilities | 4.22 M | 6.24 M | 9.26 M | 10.74 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -29.81 M | -49.28 M | -60.27 M | -57.28 M |
| Investing CF | 47.27 M | 33.49 M | 27.66 M | -112.17 M |
| Financing CF | 0.02 M | 5.2 M | 0.14 M | 51.08 M |
| Free CF | -29.81 M | -49.28 M | -60.28 M | -57.34 M |
| Capex | — | — | -0.01 M | -0.05 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | 22.52% | -11.87% | — | — |
| Profit Margin % | -9084.12% | — | — | — |
| Operating Margin % | -9511.95% | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | -9491.35% | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2026-02-06 | 1:0.125 |